Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
暂无分享,去创建一个
V. Miller | A. Sapino | B. Alexander | Siraj M. Ali | S. Bellomo | S. Marsoni | Z. Miedzybrodzka | M. Apicella | S. Corso | S. Giordano | A. Gloghini | A. Sartore-Bianchi | S. Siena | R. Petty | S. Ughetto | C. Marchiò | F. Morano | F. Pietrantonio | A. Schrock | G. dè Manzoni | G. Baiocchi | M. Bencivenga | S. Molfino | Å. Dahle-Smith | M. Prisciandaro | U. Fumagalli | S. Corallo | M. Di Bartolomeo | S. de Pascale | R. Reddavid | M. Degiuli | G. Sgroi | E. Rausa | A. Petrelli | D. Moya-Rull | A. Sottile | C. Migliore | Laura D’Errico | Jessica K. Lee | J. Ross | Stefania Durando | Daniela Conticelli | G. De Manzoni | Annalisa Petrelli
[1] L. Kinch,et al. Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers , 2019, SSRN Electronic Journal.
[2] A. Bass,et al. A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. , 2019, Cancer research.
[3] V. Adamo,et al. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Hilsenbeck,et al. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] M. Shah,et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. , 2018, The Lancet. Oncology.
[6] F. Pietrantonio,et al. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. , 2018, Pharmacogenomics.
[7] L. Farahmand,et al. Monoclonal antibody‐based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER , 2018, The Journal of pharmacy and pharmacology.
[8] P. Tan,et al. Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers , 2018, Nature Communications.
[9] A. Bass,et al. Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts12 , 2018, Neoplasia.
[10] Leah M Chase,et al. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.
[11] G. Pruneri,et al. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study , 2017, Clinical Cancer Research.
[12] James X. Sun,et al. Genomic Profiling of Small-Bowel Adenocarcinoma , 2017, JAMA oncology.
[13] Marion Procter,et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.
[14] Z. Miedzybrodzka,et al. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S Marsoni,et al. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort , 2017, Oncogene.
[16] A. Bass,et al. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma , 2017, Nature Communications.
[17] J. Bariwal,et al. Review on EGFR Inhibitors: Critical Updates. , 2016, Mini reviews in medicinal chemistry.
[18] S. Corso,et al. How Can Gastric Cancer Molecular Profiling Guide Future Therapies? , 2016, Trends in molecular medicine.
[19] P. Lu,et al. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single‐Arm, Multicenter Phase 2 Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Patricia Grob,et al. Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor , 2015, Molecular and Cellular Biology.
[21] J. Marshall,et al. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies , 2015, Cancer.
[22] U. Nielsen,et al. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic , 2015, Molecular Cancer Therapeutics.
[23] Jason G. Jin,et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.
[24] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[25] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[26] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[27] Wei Zhang,et al. Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy , 2015, Proceedings of the National Academy of Sciences.
[28] P. Comoglio,et al. Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence , 2014, Molecular oncology.
[29] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[30] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[31] D. Ferry,et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. , 2014, The Lancet. Oncology.
[32] Shibing Deng,et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.
[33] Atsushi Tanaka,et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.
[34] S. Nelson,et al. Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.
[35] M. Hidalgo,et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Hiroyuki Miyoshi,et al. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture , 2013, Nature Protocols.
[37] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[38] Yiqiang Liu,et al. A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy , 2013, Scientific Reports.
[39] Wei-ping Xu,et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. , 2013, Archives of medical research.
[40] A. Ciliberto,et al. Threshold-controlled ubiquitination of the EGFR directs receptor fate , 2013, The EMBO journal.
[41] A. Wotherspoon,et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.
[42] Galina Kurteva,et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.
[43] Jeremy Wazny,et al. Xenome—a tool for classifying reads from xenograft samples , 2012, Bioinform..
[44] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[45] Zhengyan Kan,et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.
[46] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[47] Y. Maehara,et al. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer , 2010, Clinical Cancer Research.
[48] P. Comoglio,et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. , 2010, Cancer research.
[49] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.
[50] C. Pyke,et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.
[51] Robert Pirker,et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.
[52] P. Comoglio,et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases , 2008, Oncogene.
[53] Christian J Stoeckert,et al. STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. , 2006, Genome research.
[54] Hongbing Zhang,et al. Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation of TSC1 or TSC2 Leads to mTOR Activation , 2004, Journal of neuropathology and experimental neurology.
[55] David J. Kwiatkowski,et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[56] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[57] Andrew Dunford,et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.
[58] K. Inoki,et al. TSC2: filling the GAP in the mTOR signaling pathway. , 2004, Trends in biochemical sciences.